ArticleAsia Pacific allergy2025
Effective desensitization in an IgE-mediated hypersensitivity reaction to tocilizumab in neuromyelitis optica.
Article in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards standardized skin testing for drug-induced allergic reactions.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica is a rare, inflammatory autoimmune disease of the central nervous system. Tocilizumab is a humanized monoclonal antibody, which targets the inhibition of the interleukin-6 receptor, a mediator with an important role in the pathophysiological mechanism of neuromyelitis optica. Hypersensitivity reactions to tocilizumab are rare, but similar to other biological drugs can elicit a hypersensitivity reaction. The authors present a case of a 50-year-old female patient, with a neuromyelitis optica, with a severe reaction at the 6th cycle of treatment. The patient was referred to Drug Allergy Consultation, where she underwent tocilizumab skin tests: intradermal test 1/1,000 with a positive result. The patient was then proposed for drug desensitization, and, to date, the patient has undergone 22 desensitization cycles, all of which were uneventful. This case emphasizes the importance of trying to phenotype the hypersensitivity reactions to monoclonal antibodies, and therefore invest in an allergy workup to make the best decision for our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.